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Abstract
Rationale
Recent work in preclinical models suggests that signalling via the pro-angiogenic and pro-
inflammatory cytokine, CXCL12 (SDF-1), plays an important pathogenic role in pulmonary
hypertension (PH). The objective of this study was to establish whether circulating concen-
trations of CXCL12α were elevated in patients with PAH and related to mortality.
Methods
Plasma samples were collected from patients with idiopathic pulmonary arterial hyperten-
sion (IPAH) and PAH associated with connective tissue diseases (CTD-PAH) attending two
pulmonary hypertension referral centres (n = 95) and from age and gender matched healthy
controls (n = 44). Patients were subsequently monitored throughout a period of five years.
Results
CXCL12α concentrations were elevated in PAH groups compared to controls (P<0.05) and
receiver-operating-characteristic analysis showed that plasma CXCL12α concentrations
discriminated patients from healthy controls (AUC 0.80, 95% confidence interval 0.73-0.88).
Kaplan Meier analysis indicated that elevated plasma CXCL12α concentration was associ-
ated with reduced survival (P<0.01). Multivariate Cox proportional hazards model showed
that elevated CXCL12α independently predicted (P<0.05) earlier death in PAH with a haz-
ard ratio (95% confidence interval) of 2.25 (1.01-5.00). In the largest subset by WHO func-
tional class (Class 3, 65% of patients) elevated CXCL12α independently predicted (P<0.05)
earlier death, hazard ratio 2.27 (1.05-4.89).
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Conclusions
Our data show that elevated concentrations of circulating CXCL12α in PAH predicted
poorer survival. Furthermore, elevated circulating CXCL12α was an independent risk factor
for death that could potentially be included in a prognostic model and guide therapy.
Introduction
Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular
resistance, mediated by structural remodelling of the pulmonary vasculature, endothelial dys-
function and inflammation [1–3]. These changes ultimately lead to right ventricular dysfunc-
tion, which is associated with higher morbidity and mortality [4]. The precise molecular
mechanisms that cause these vascular abnormalities remain to be fully elucidated. In a previous
study identifying genes selectively upregulated in the hypoxic lung we showed that CXCR7, a
receptor for the pro-angiogenic chemokine CXCL12 (SDF-1), was selectively up-regulated in
primary human pulmonary microvascular endothelial cells in response to hypoxia but re-
mained unchanged in hypoxic systemic microvascular cells [5]. This selective increase in ex-
pression was also observed in vivo in the hypoxic rodent lung and in the endothelium of
explanted human lungs from idiopathic (IPAH) patients [6]. We and others have also observed
that both CXCL12 and a second CXCL12 receptor, CXCR4, were more highly expressed in re-
modelled vessels in hypertensive diseases compared to control lungs [6, 7]. Subsequently, the
important role of CXCL12 in hypoxic PH was established by studies showing that inhibition of
CXCL12 signalling via either of its two receptors, CXCR4 or CXCR7, attenuates hypoxia-in-
duced PH in rodents [8–12]. Given these findings, the objective of the present study was to es-
tablish whether circulating concentrations of CXCL12α were increased in the plasma of
patients with pulmonary hypertension and whether elevated concentrations predicted a poorer
prognosis. Results from our study suggest that elevated circulating CXCL12α is an independent
risk factor for reduced survival.
Material and Methods
Dublin patients and ELISA analysis
All patients attending the national pulmonary hypertension unit in the Mater Misericordiae
University Hospital (MMUH), a referral centre for the assessment and treatment of PAH, be-
tween 7th March 2007 and 22nd July 2010 were recruited to the study. The study protocol was
approved by the Mater Misericordiae Hospital ethics research committee and informed written
consent was obtained from all study participants. BMPR2 mutation status was not ascertained.
All patients (n = 43) had a diagnosis of PH confirmed by right heart catheterization demon-
strating a mean pulmonary arterial pressure (mPAP) greater than 25 mmHg together with a
pulmonary capillary wedge pressure less than or equal to 15 mmHg. Patients were recruited
who had a diagnosis of PAH (Group 1) based on the Nice classification 2013 [3]; these were pa-
tients with idiopathic PAH (IPAH; Group 1.1) or connective tissue disease PAH (CTD-PAH,
Group 1.4.1). Patient characteristics were recorded within 30 days of recruitment into the
study from the clinical notes; more detailed information on patient diagnosis is available in S1
File. Eight patients were treatment naïve (incident disease cohort) whereas the remaining 35
patients (prevalent disease cohort) were receiving specific PAH therapy (Table 1). Survival sta-
tus for the Dublin cohort was finally ascertained on 31st July 2012 (i.e. 63-month follow-up
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period) by later clinical review, communication with the referring physician or checking the
registry of deaths. Since many deaths occurred distant from the pulmonary hypertension cen-
tre, all-cause mortality was recorded to avoid bias in ascertaining the cause of death; one CTD
patient was lost to follow-up. The Dublin cohort included a sub-group of patients (n = 12) in-
cluded in our previous study and subsequently followed clinically for an extended period [6].
Venous blood samples were drawn, anti-coagulated and the plasma separated by centrifuga-
tion. Plasma samples were divided into aliquots and stored at −80°C before analysis. CXCL12α
concentrations in undiluted plasma samples were measured by ELISA (DSA00—R&D Sys-
tems) in Dublin.
Sheffield patients and ELISA analysis
Plasma samples were obtained from all patients referred to the pulmonary vascular disease
unit in the Royal Hallamshire Hospital (Sheffield, UK), a referral centre for the assessment and
treatment of PAH, between 28th September 2009 and 17th November 2011, as previously de-
scribed [13]. Samples were obtained with Royal Hallamshire Hospital research ethics commit-
tee approval and informed written consent was obtained from all subjects. BMPR2 mutation
status was not ascertained. Patients (n = 52) who had a diagnosis of IPAH or CTD-PAH, based
on the criteria outlined above for the Dublin Cohort, were included in the study and had not
received specific treatment for PH (included in the incident disease cohort) prior to the date of
plasma sampling (Table 1). Venous blood was anti-coagulated and the plasma separated by
Table 1. Patient characteristics for Dublin (n = 43) and Sheffield cohorts (n = 52) at time of diagnostic catheter study.
Dublin Cohort Shefﬁeld Cohort
Characteristic IPAH CTD-PAH IPAH CTD-PAH
Age (yrs) 48 (38–59) 62 (49–71) 64 (44–68) 64 (61–70)
Gender (F:M) 16:5 18:4 14:11 17:10
Ethnicity Caucasian 19 22 21 27
Asian 2 - 4 -
mPAP (mmHg) 55 (42–61) 41 (28–50) 53 (49–63) 38 (30–46)
PCWP (mmHg) 10 (8–12) 10 (7–12) 11 (8–12) 12 (8–13)
mRAP (mmHg) 7 (5–10) 7 (4–8) 11 (8–15) 9 (4–10)
PVR, dyn.s/cm5 864 (446–1085) 431 (332–738) 793 (539–1200) 412 (279–570)
WHO FC I 1 1 0 0
II 11 5 3 4
III 7 14 21 20
IV 2 2 1 3
6MWT distance (m) 425 (313–478) 375 (285–442) - -
ISWT distance (m) - - 190 (70–263) 110 (70–205)
PAH therapies None 2 6 25 27
ERA 16 11 0 0
PDE5 inhibitor 9 6 0 0
Prostacyclin analogues 7 4 0 0
Data presented as median (quartiles). Walk distance was measured by the 6-minute walk test (6MWT) in Dublin and the incremental shuttle walk test
(ISWT) in Shefﬁeld. One patient from Dublin was subsequently lost to follow-up (CTD patient, WHO-FC 1).
Deﬁnition of abbreviations: IPAH = Idiopathic pulmonary arterial hypertension, CTD = Connective tissue disease, mPAP = Mean Pulmonary Artery
Pressure, mRAP = Mean Right Atrial Pressure, PCWP = Pulmonary Capillary Wedge Pressure, PVR = pulmonary vascular resistance, WHO FC = World
health organization functional class, ERA = Endothelin receptor antagonist, PDE5 = Phosphodiesterase-5 inhibitor.
doi:10.1371/journal.pone.0123709.t001
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centrifugation. Within 24 hours of blood sampling the age, gender and results of clinical assess-
ment were recorded as for the Dublin Cohort, with the exception of the results of an incremen-
tal shuttle walk test which was used instead of the 6-minute walk test used in Dublin. Survival
status was finally ascertained on 20th June 2014 (i.e. 57-month follow-up period) by later clini-
cal review, communication with the referring physician or checking the registry of deaths.
Since many deaths occurred distant from the pulmonary hypertension centre, all-cause mortal-
ity was recorded to avoid bias in ascertaining the cause of death; no patient was lost to follow-
up. Plasma samples were shipped to Dublin where CXCL12α concentrations in undiluted plas-
ma samples were measured by ELISA (DSA00—R&D Systems) according to the manufactur-
er’s protocol.
Control cohort and interassay controls
A panel of healthy non-smoking controls (n = 44), with no history of lung disease, was re-
cruited from unaffected relatives of patients or unaffected relatives and colleagues of scientists
in Dublin and processed as described above for the Dublin cohort. Undiluted plasma samples
were measured by ELISA (DSA00—R&D Systems) in Dublin so that for each patient in each of
the separate patient groups (IPAH-Dublin, CTD-PAH Dublin, IPAH-Sheffield, CTD-PAH
Sheffield), a plasma sample could be obtained from a normal subject whose age and gender
matched that of the patient. Four PAH plasma samples were assessed on all plates to act as
interassay controls. For detailed methods, see S1 File.
Statistical analyses
CXCL12α concentrations are presented as scatter-plots or medians (quartiles) and statistical
comparisons made using the Mann-Whitney U test. The relationship between patient charac-
teristics and biomarkers was assessed by Spearman rank test, or Chi-Square test for categorical
variables. Receiver operating characteristic (ROC) curves were used to examine the usefulness
of circulating CXCL12α concentrations in discriminating patients with PAH from healthy con-
trols. All Kaplan-Meier analyses were performed using time from sampling to death/census, as
assessed by the log-rank (Mantel-Cox) test. Univariate and multivariate analyses were con-
ducted using Cox proportional hazards model with survival as the dependent variable. Inde-
pendent variables, collected at the time of plasma sampling in both Dublin and Sheffield and
entered into the analysis, were those identified in previous studies as of potential prognostic
importance i.e. gender, age, WHO functional class, disease aetiology and interval from diagno-
sis to study enrolment (prevalent or incident disease) [14, 15]. There were no missing data in
any of the variables included in the Cox Proportional analyses. Selected variables were input
into a multivariable Cox proportional hazards model to identify independent prognostic fac-
tors; the model was fit with a p<0.10 entry criteria. All statistical analyses were performed with
SPSS statistics version 20 software (IBM, USA); a P value less than 0.05 was considered statisti-
cally significant.
Results
CXCL12α concentrations in patient cohorts
All ELISA analyses were carried out in Dublin, the ELISA kit (DSA00; R&D Systems) used al-
lows the quantitative determination of human isoform CXCL12α. Patient characteristics for
the Dublin group are reported in Table 1; one CTD patient (WHO-FC 1) was subsequently lost
to follow-up due to emigration. CXCL12α concentrations were significantly elevated in pa-
tients with IPAH and CTD-PAH when compared to non-diseased age and gender matched
CXCL12αConcentrations in Pulmonary Arterial Hypertension
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controls (Fig 1 and Table A in S1 File). Given these findings, we decided to further explore the
clinical relevance of circulating CXCL12α concentrations by including patients from a second
PH centre (Table 1 - Sheffield cohort). CXCL12α concentrations in plasma samples collected
in Sheffield independently confirmed our finding in the Dublin cohort; CXCL12α concentra-
tions were significantly elevated in patients with IPAH and CTD-PAH (Fig 2 and Table B in
S1 File). No significant differences between CXCL12α concentrations in PAH and CTD were
observed between the Dublin and Sheffield cohorts (Figs 1 and 2). Since our patient cohort
consisted of both incident and prevalent patients, we first examined if receiving specific PAH
therapy had an effect on CXCL12α concentration. We observed no significant difference in
CXCL12α concentrations between treatment naïve patients, with a median (lower-upper quar-
tile) of 2928 pg/ml (2349–3306 pg/ml) and those on specific PAH therapy (2613 pg/ml (2208–
3085 pg/ml). Since PAH is a rare disease, the study cohorts were amalgamated in all subsequent
analyses. Using ROC curve analysis we observed that plasma CXCL12α concentrations distin-
guished between healthy (n = 44) and PAH patients (n = 95) (Fig 3). We noted a positive corre-
lation (Rho value = 0.379; p = 0.0003) between CXCL12α levels and mean right atrial pressure
(mRAP) but not with any other baseline haemodynamic measurements (Table 2).
Survival analysis in the combined Dublin and Sheffield cohorts
During the 63-month period of follow-up in Dublin, 11 of the 42 patients for whom we had fol-
low-up data died whereas 24 of the 52 patients died during the 57-month period of follow-up
in Sheffield. Kaplan-Meier analysis of cumulative survival indicated that patients with higher
CXCL12α concentrations (> group median of 2,841 pg/ml) had a significantly poorer survival
over time compared to patients with a lower plasma CXCL12α (< group median) (Fig 4A;
p = 0.022) over the course of the study; 49% of patients with high plasma CXCL12α died
Fig 1. Plasma CXCL12α concentrations in pulmonary hypertensive patients (Dublin cohort) and age and gender matched controls.CXCL12α
concentrations were significantly elevated in plasma samples from (A) idiopathic pulmonary arterial hypertensive (IPAH) patients (median: 2700, quartiles:
2174–3085 pg/ml) compared to age and gender matched controls (1938, 1784–2210 pg/ml) and from (B) connective tissue disease PAH (CTD-PAH)
patients (2506, 2314–3180 pg/ml) compared to age and gender matched controls (2251, 1839–2488 pg/ml). Horizontal bars indicate median values.
doi:10.1371/journal.pone.0123709.g001
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compared to 26% of those with low plasma CXCL12α (Fig 4B). Interestingly, the median
CXCL12α concentration in the patient group identified non-disease controls with high speci-
ficity (i.e. approx. 97.5%); this suggested those PAH patients whose CXCL12α concentration
lie above normal range have a poorer prognosis.
Univariate analysis of risk factors for death revealed that high plasma CXCL12α levels, male
gender, high WHO functional class, older age and incident disease were significantly associated
with a shorter survival time (Table 3). Multivariate analysis showed that elevated CXCL12α
was an independent risk factor (P = 0.047) for reduced survival in PAH patients, increasing the
hazard ratio by 2.3-fold (Table 3). In addition, male gender (P = 0.003) and high WHO func-
tional class (P = 0.009) were also independent risk factors for reduced survival in PAH
(Table 3).
Survival analysis in WHO functional class 3 patients
We confirmed that the well-established risk factor for reduced survival in PAH, namely elevat-
ed WHO-FC, was strongly associated with reduced survival (Fig 5A; P = 0.0002); PAH patients
in a combined WHO functional class 1 & 2 had a significantly better survival (i.e. 4% of pa-
tients died) compared to those in WHO functional class 3 & 4 (i.e. 49% of patients died; Fig
5B). Moreover, of those patients in the combined WHO functional class 3 & 4 group, 62 were
in WHO functional class 3 and 30 (48%) of these died during the course of the study. In order
to determine whether CXCL12α concentrations could discriminate between those with a good
or poor prognosis in this the largest group by functional class, we next examined whether ele-
vated plasma CXCL12α concentrations could predict reduced survival in WHO functional
class 3 patients. We found that patients with high CXCL12α had a significantly poorer survival
rate when compared to those with low CXCL12α (Fig 5C; P = 0.015); that is to say that 65% of
Fig 2. Plasma CXCL12α concentrations in pulmonary hypertensive patients (Sheffield cohort) and age and gender matched controls.CXCL12α
concentrations were significantly elevated in plasma samples from (A) idiopathic pulmonary arterial hypertensive (IPAH) patients (median: 2845 pg/ml,
quartiles: 2278–3320 pg/ml) compared to age and gender matched controls (2181, 1932–2457 pg/ml) and from (B) connective tissue disease PAH
(CTD-PAH) patients (2903, 2332–3208 pg/ml) compared to age and gender matched controls (2143, 1924–2360 pg/ml). Horizontal bars indicate
median values.
doi:10.1371/journal.pone.0123709.g002
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patients with high CXCL12α died over the course of the study whereas only 32% of patients
with a low CXCL12α died (Fig 5D).
Analysis of risk factors for survival in WHO-FC 3 patients revealed that, similar to the entire
PAH group, elevated CXCL12α was an independent risk factor for survival (P = 0.037), in-
creasing the hazard ratio by more than twofold (Table 4). In addition, male gender (P = 0.008)
was also an independent risk factor for reduced survival (Table 4).
Discussion
We have demonstrated for the first time, in a cohort of patients with pulmonary arterial hyper-
tension, that plasma concentrations of CXCL12α are elevated compared to normal controls. In
addition, we have demonstrated that elevated levels of CXCL12α are independently associated
with reduced survival, and that higher CXCL12α concentration is an independent risk factor
for an earlier death.
CXCL12 is a potent pro-angiogenic chemokine that signals via two receptors, CXCR4 and
CXCR7 [16, 17]. Previous evidence from studies in rodents had demonstrated that CXCL12,
Fig 3. Receiver operating characteristic (ROC) analysis. Receiver operating characteristic (ROC)
analysis showing the discrimination of healthy controls (n = 44) from PAH patients ((IPAH and CTD-PAH);
n = 95) cohorts.
doi:10.1371/journal.pone.0123709.g003
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acting through both these receptors, plays an important role in the pathogenesis of PH [8–12].
Since CXCL12 is a secreted chemokine, we hypothesised that plasma CXCL12 concentrations
would be elevated in patients with PAH and would predict a poorer outcome. To examine this
Table 2. Relationship between CXCL12α concentrations and clinical indices of disease severity in PAH patients (n = 95).
Clinical Variable CXCL12α (pg/ml) < Median# CXCL12α (pg/ml) > Median# Correlations (Rho) P Value
Age (Yrs) 63 (47–70) 61 (47–69) -0.045 0.665
Gender (F:M) 35:13 30:17 0.341
mPAP (mmHg) 46 (34–55) 50 (38–60) 0.152 0.149
PCWP (mmHg) 10 (7–12) 11 (8–14) 0.162 0.132
mRAP (mmHg) 7 (4–9) 10 (7–14) 0.379 0.0003*
PVR, dyn.s/cm5 539 (379–800) 752 (344–1085) 0.111 0.332
CO (L/min) 4.9 (4.2–5.7) 4.5 (3.6–5.9) -0.071 0.548
WHO FC I 2 0 0.566
II 11 12
III 31 31
IV 4 4
ISWT (m) 195 (93–270) 120 (70–230) -0.183 0.213
6MWT (m) 410 (314–475) 408 (281–450) -0.048 0.744
Data are presented as median (lower-upper quartile)
*P<0.05 was considered statistically signiﬁcant.
Deﬁnition of abbreviations: mPAP = Mean Pulmonary Artery Pressure, PCWP = Pulmonary Capillary Wedge Pressure, mRAP = Mean Right Atrial
Pressure, PVR = pulmonary vascular resistance, CO = Cardiac output, WHO-FC = World Health Organization functional class, ISWT = Incremental
Shuttle Walk Test (Shefﬁeld only) and 6MWT = Six minute walk test (Dublin only).
#median value = 2,838 pg/ml
doi:10.1371/journal.pone.0123709.t002
Fig 4. CXCL12α concentrations and survival in the combined Dublin and Sheffield PAH patients. (A) Kaplan Meier survival analysis among PAH
patients (IPAH and CTD-PAH) with CXCL12α concentrations less than the median (blue line) and greater than the median (green line). The table represents
the number of patients remaining (did not die/were not censored) in the study at the indicated time point. Note that this analysis was carried out on 94 of 95
patients; 1 patient was lost to follow-up due to emigration. (B) Number of deaths in entire cohort.
doi:10.1371/journal.pone.0123709.g004
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premise, we measured plasma CXCL12α concentrations in PAH patients attending the
MMUH pulmonary hypertension clinic in Dublin. Initial findings of significantly higher
CXCL12α concentrations in PH patients compared to age and gender matched controls (Fig 1)
supported this hypothesis and were subsequently confirmed in a second cohort of patients re-
cruited in Sheffield (Fig 2). These findings contrast with previous reports that plasma
CXCL12α was not significantly elevated in PAH patients [18, 19]. One striking difference be-
tween patients in the current study and those in the Farha et al study [18] that may explain the
difference in findings is that a substantial majority of the latter patients (58%) were being treat-
ed with prostacyclin analogues whereas only 12% of those we studied (11 of 95 patients) were
receiving such agents (Table 1). Prostacyclin agonists potently suppress cytokine secretion by
inhibition of NFκB mediated gene expression both in vitro and in pulmonary hypertensive pa-
tients [20, 21]. Since CXCL12 is an NFκB regulated chemokine [22], prostacyclin therapy in
PH may suppress plasma CXCL12 concentrations, thus accounting for the absence of elevation
of CXCL12 in patient groups where a high proportion were receiving such treatment [18].
However, direct experimental evidence in support of this proposed mechanism requires future
study. Nonetheless, further evidence supporting the finding of elevated CXCL12α concentra-
tions in PAH was provided by ROC curve analysis, which showed that plasma CXCL12α con-
centrations could discriminate between healthy controls and PAH patients (Fig 3).
We had initially hypothesised that if elevated CXCL12 played a significant mechanistic role
in the pathogenic process underlying PH, then higher CXCL12 concentrations would predict
Table 3. Univariate andmultivariate Cox proportional hazards model analysis of survival in PAH patients (n = 94).
Alive [n
(%)]
Dead [n
(%)]
UnivariateP
value
UnivariateHazard Ratio
(95% CI)
MultivariateP
value
MultivariateHazard Ratio
(95% CI)
CXCL12α
concentration
Low CXCL12α 35 (74%) 12 (26%) 0.026 2.22 (1.10–4.47) 0.047* 2.25 (1.01–5.00)
High CXCL12α 24 (51%) 23 (49%)
Gender
Female 47 (73%) 17 (27%) 0.001 3.01 (1.55–5.87) 0.003* 2.82 (1.42–5.59)
Male 12 (40%) 18 (60%)
WHO_FC
Class 1 & 2 23 (96%) 1 (4%) 0.006 16.03 (2.19–117.35) 0.009* 15.44 (2.0–119.2)
Class 3 & 4 36 (51%) 34 (49%)
Treatment status
Prevalent 26 (76%) 8 (24%) 0.045 2.25 (1.02–4.95) 0.628 0.79 (0.31–2.02)
Incident 33 (55%) 27 (45%)
Disease Aetiology
IPAH 33 (72%) 13 (28%) 0.092 1.81 (0.91–3.60) 0.180 1.61 (0.80–3.25)
CTD 26 (54%) 22 (46%)
Age
Low Age 39 (75%) 13 (25%) 0.010 2.46 (1.24–4.88) - -
High Age 20 (48%) 22 (52%)
Selected variables with p<0.10 in univariate analysis were included in the multivariate (MV) analysis
*p<0.05 considered signiﬁcant in MV analysis.
Deﬁnition of abbreviations: IPAH = Idiopathic pulmonary arterial hypertension, CTD = Connective tissue disease, WHO FC = World health organization
functional class. Low CXCL12α <Median (2,841 pg/ml), High CXCL12α >Median (2,841 pg/ml). Low Age<Median (63 yrs), High Age>Median (63 yrs).
Prevalent: Receiving PAH therapy; Incident: Treatment naïve.
doi:10.1371/journal.pone.0123709.t003
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poorer disease outcome. It was therefore interesting to note that all of our controls, with the ex-
ception of one, had a CXCL12α concentration below the median value of the patient groups.
This suggests that PAH patients whose CXCL12α concentration lies above the range observed
in healthy controls might have a poorer prognosis. Indeed, initial Kaplan-Meier survival analy-
sis clearly demonstrated that high circulating CXCL12α significantly reduced survival (Fig 4).
In agreement with previously published results, multivariate Cox proportional hazards model
Fig 5. CXCL12α concentrations and survival in the combined Dublin and Sheffield PAH patients (IPAH and CTD-PAH) in WHO functional class 3.
(A) Kaplan Meier analysis confirming that WHO functional class is strongly predictive of mortality (p = 0.0002) in PAH patients (IPAH and CTD-PAH). The
table represents the number of patients remaining (did not die/were not censored) in the study at the indicated time point. (B) Number of patients that died in
the different WHO functional classes. (C) Stratification of functional class 3 PAH patients (p = 0.015) on CXCL12α concentrations less than (blue line) and
greater than the median (green line). The table represents the number of patients remaining (did not die/were not censored) in the study at the indicated time
point. (D) Number of deaths in WHO functional class 3.
doi:10.1371/journal.pone.0123709.g005
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(Table 3) demonstrated an increased hazard associated with male gender and highWHO-func-
tional class [14]. In addition to these recognised confounding factors, we now report that ele-
vated circulating CXCL12α is an independent risk factor for survival that could potentially be
included in a prognostic model. Taken together with previous evidence from animal studies
that blockade of CXCL12α or its cognate receptors ameliorate the development of PAH [8–
12], our finding that high circulating CXCL12α concentrations predict a poorer outcome in
patients with PH suggests that CXCL12α is an important pathogenic mediator of this disease
process.
CXCL12α correlated significantly with mean right atrial pressure (mRAP) in patients
(Table 2); mRAP is strongly associated with reduced survival in PAH [23]. However,
CXCL12α was not significantly correlated with any other haemodynamic variable (Table 2).
This lack of correlation of circulating cytokines (or other circulating factors) that predict sur-
vival outcome in PAH, with haemodynamic variables, is a well-established observation. For ex-
ample, in a study of five biomarkers in PAH, Rhodes et al found that red cell distribution width
(RDW) was not significantly correlated with any haemodynamic variable, even though it was
the best in distinguishing patients with a higher risk of death. Moreover, RDW was the only
marker, other than N-terminal pro-brain natriuretic peptide (NT-proBNP), which added inde-
pendent predictive value in a Cox’s multivariate regression analysis [24]. Similarly, in a more
recent study, the same group found that reduced microRNA–150 was an independent predic-
tor of poor survival but was not significantly correlated with pulmonary arterial pressure, pul-
monary vascular resistance, cardiac output or right atrial pressure [13]. The reasons for such
lack of correlation with haemodynamic variables is unknown but suggests that such changes in
Table 4. Univariate andmultivariate Cox proportional hazards model analysis of survival in PAH patients categorised asWHO-functional class 3
(n = 62).
Alive [n
(%)]
Dead [n
(%)]
UnivariateP
value
UnivariateHazard Ratio
(95% C.I.)
MultivariateP
value
MultivariateHazard Ratio
(95% C.I.)
CXCL12α
concentration
Low CXCL12α 21 (68%) 10 (32%) 0.019 2.50 (1.17–5.36) 0.037* 2.27 (1.05–4.89)
High CXCL12α 11 (35%) 20 (65%)
Gender
Female 27 (63%) 16 (37%) 0.004 2.93 (1.42–6.06) 0.008* 2.68 (1.29–5.56)
Male 5 (26%) 14 (74%)
Treatment status
Prevalent 10 (63%) 6 (37%) 0.313 1.59 (0.65–3.89) - -
Incident 22 (48%) 24 (52%)
Disease Aetiology
IPAH 15 (54%) 13 (46%) 0.867 1.06 (0.51–2.20) - -
CTD 17 (50%) 17 (50%)
Age
Low Age 10 (100%) - 0.087 2.20 (0.89–5.43) - -
High Age 12 (28%) 30 (72%)
Selected variables with p<0.10 in univariate analysis was included in the multivariate (MV) analysis
*p<0.05 considered signiﬁcant in MV analysis.
Deﬁnition of abbreviations: IPAH = Idiopathic pulmonary arterial hypertension, CTD = Connective tissue disease, WHO FC = World health organization
functional class. Low CXCL12α <Median (2,841 pg/ml), High CXCL12α >Median (2,841 pg/ml). Low Age<Median (63 yrs), High Age>Median (63 yrs).
Prevalent: On PAH therapy; Incident: Treatment naïve.
doi:10.1371/journal.pone.0123709.t004
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peripheral blood indices may be due to mechanisms that that are independent of right ventric-
ular compromise.
It is well established that WHO functional class is an excellent predictor of outcome in PAH
[25], an observation that was replicated in the present study (Fig 5A and 5B). Functional class
is an important factor in the choice of PAH therapy [26] but the clinical usefulness of function-
al class both for establishing prognosis and guiding therapy is limited because the great majori-
ty of patients diagnosed with PAH are in functional class III and the overwhelming majority of
early deaths are in this group [13, 23, 27, 28]. When we examined whether CXCL12α concen-
trations could discriminate between those with a good or those with a poor prognosis within
functional class III, we found a strikingly worse outcome in those with higher plasma
CXCL12α concentrations (Fig 5C and 5D). What is particularly noteworthy is that multivariate
Cox proportional hazards model showed that elevated CXCL12α was an independent risk fac-
tor for death in WHO functional class 3 PAH patients (Table 4). These data demonstrate that
measurement of plasma CXCL12α concentrations gives prognostic information additional to
that provided by functional classification, further supporting the hypothesis that increased
CXCL12αmay be an important pathogenic mediator in the development and progression of
PAH and may provide useful information to guide therapy.
It is important to acknowledge a number of limitations of our study. Since PAH is a rare dis-
ease the number of patients in our study are restricted and further independent studies in other
patient centres will be needed to confirm our finding that elevated circulating CXCL12α is in-
dependently associated with a poorer prognosis in PAH. All patients included in our study had
been referred to regional centres with a specific expertise in the treatment of PAH. Given the
difficulty of diagnosing this condition, these represent a cohort of patients at a later stage in the
natural history of the condition with more severe disease. Therefore our findings may not
apply to patients at the earliest stages in the disease course. We also noted that the gender dis-
tribution and median age in IPAH patients were different in the two PH centres; IPAH patients
from Sheffield were predominantly male and older when compared to those from Dublin. A
further limitation of our study is that patients were predominantly Caucasian adults and there-
fore our findings may not necessarily generalise to other ethnic groups and to children and
young adults with this condition. Additional studies are required to determine the usefulness
of plasma CXCL12α concentrations as an independent risk factor for reduced survival in those
other ethnic groups and age groups.
The question that then arises is how might elevated CXCL12α be causing increased mortali-
ty? Signalling via CXCL12 has been shown to be involved in several processes implicated in the
development of PH, such as disordered endothelial cell proliferation, inflammation and pro-
genitor cell recruitment. Expression of CXCL12 is markedly increased in the pulmonary vascu-
lar endothelium and the endothelium of the vasa vasorum of larger pulmonary vessels
removed from patients with PH when compared to control lungs [6, 18, 19] and endothelial
cells isolated from the lungs of PAH patients produce greater amounts of CXCL12 in vitro than
cells from control lungs [18]. Furthermore, the expression of both CXCL12 receptors, CXCR4
and CXCR7, is increased in the vascular endothelium of lungs from PAH patients [6, 19].
CXCL12 acts via the CXCR7 receptor to stimulate microvascular endothelial cell proliferation
and via CXCR4 to mediate chemotactic endothelial cell migration [6]. CXCL12 is also pro-in-
flammatory and is a potent chemoattractant for T-lymphocytes and monocytes in vitro [29]
and stimulates progenitor cell recruitment to the pulmonary vasculature [8, 10, 11, 30]. Impor-
tantly blockade of CXCR4 or CXCR7 attenuates the development of hypoxic PH in in vivo mu-
rine studies [8, 10, 11] and antagonism of CXCR7 has recently been reported to ameliorate PH
in new-born mice exposed to hypoxia for two weeks [9]. Taken together with our findings in
patients with PAH, these data strongly suggest an important pathogenic role for elevated
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CXCL12 in the development of the vascular abnormalities underlying human PH. However it
is important to stress that although we have identified an independent association between ele-
vated plasma CXCL12α concentrations and reduced survival, causality cannot be assumed as it
is also possible that elevated CXCL12α is a reflection of more severe disease; further work is
needed to investigate this possibility.
In summary, we found that plasma CXCL12α concentrations were elevated in patients with
pulmonary hypertension compared to healthy controls. We further showed that elevated circu-
lating CXCL12α is an independent risk factor for reduced survival that could potentially be in-
cluded in a prognostic model and guide therapy in clinical practice. Additional studies in larger
patient cohorts, to establish the reliability and overall usefulness of circulating CXCL12α levels
in predicting survival, are now required.
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